Objective The aim of this study was to investigate whether remedial hydration (RH) reduces the incidence of contrast-induced nephropathy (CIN) and short-term adverse events in ST-elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI). Methods A total of 216 consecutive STEMI patients were prospectively and randomly assigned into two groups: 108 patients in the RH group and 108 patients in the no RH (control) group. The serum creatinine (SCr) and creatinine clearance (CCr) levels were measured on admission and at 24, 48 and 72 hours after primary PCI. The rates of CIN and short-term adverse events were analyzed for each group. After surgery, the patients were categorized into four groups according to the Mehran risk score: low (! 5, n =98), moderate (6-10, n=56), high (11-15, n=40) or very high (" 16, n=22). Results The incidence of CIN in the RH group was lower than that observed in the control group (22/108; 20.4% vs. 38/108; 35.2%, p<0.05). The subgroup analysis showed that the rate of CIN was lower in the moderate (6/29; 20.7% vs. 13/30; 43.3%, p<0.10) and significantly lower in both the high (5/21; 23.8% vs. 10/18; 55.6%, p<0.05) and very high score groups (3/12; 25.0% vs. 8/12; 66.7%, p<0.05) among the RH patients compared to the controls. At 24, 48 and 72 hours after PCI, the patients in the RH group exhibited lower SCr levels and higher CCr levels than the patients in the control group (both p<0.05). A lower incidence of in-hospital clinical events was also observed in the RH group. Conclusion Remedial hydration decreases the occurrence of CIN and improves the short-term prognosis of STEMI patients undergoing primary PCI.
Introduction
The growing number of coronary angiographic procedures requiring contrast media has triggered a parallel increase in the incidence of contrast-induced nephropathy (CIN). The development of CIN is associated with increased short-term and long-term morbidity and mortality (1, 2) . Increasing evidence has demonstrated that primary percutaneous coronary intervention (PCI) improves the myocardial salvage and survival rates of patients with acute myocardial infarction (AMI) (3, 4) . However, the risk of CIN is significantly higher among patients with AMI undergoing primary PCI than the general population treated with elective PCI for multiple reasons (5) .
In 1981, Eisenberg claimed that renal failure after angiography could be avoided with hydration, and providing adequate hydration has been shown to be an essential method for preventing CIN (6) . However, an insufficient duration of prophylactic hydration for renal protection is a potential factor contributing to the higher risk of CIN in AMI patients (7, 8) . To date, the effects of remedial hydration in ST-elevation myocardial infarction (STEMI) patients undergoing primary PCI remain uncertain. We therefore performed a prospective, randomized, open-labeled trial to test the hypothesis that remedial hydration is more effective at inhibiting CIN and has beneficial effects on short-term outcomes in STEMI patients undergoing primary PCI.
Materials and Methods

Study population
Between August 2009 and October 2012, 216 consecutive STEMI patients treated with primary PCI in the East Hospital (Shanghai, China) coronary care unit were enrolled in this study. Patients were included if they had been admitted within 12 hours of the onset of chest pain or chest distress lasting for at least 30 minutes with electrocardiography (ECG) ST-segment elevation of at least 0.2 mV in two or more contiguous leads and/or the development of new left bundle-branch block associated with elevation in the levels of creatinine kinase or its MB isozyme to at least two times that of normal. The exclusion criteria included chronic peritoneal or hemodialysis treatment, exposure to radiographic contrast within the previous two days, any allergies to radiographic contrast medium and/or a coronary anatomy not suitable for PCI or primary bypass grafting. The ethics committee of our institution approved the present study, and all patients provided their written informed consent.
Definition
The primary endpoint was the development of CIN, defined as a 0.5-mg/dL (44 mmol/L) increase in the serum creatinine (SCr) level or 25% increase compared with the baseline value observed within 72 hours after the administration of contrast medium (9) . The level of creatinine clearance (CCr) was estimated using the Modification of Diet in Renal Disease study equation (10) . Anemia was defined according to the World Health Organization criteria, including a baseline hemoglobin value of <13 g/dL for men and <12 g/dL for women (11) . Hypotension was defined as a systolic blood pressure of <80 mm Hg lasting for at least one hour requiring inotropic support with medications and/ or an intra-aortic balloon pump within 24 hours of the procedure. Diabetes was defined as a diagnosed history of the condition, a fasting plasma glucose level of 126 mg/dL or above, a random plasma glucose level of 200 mg/dL or higher or an HbA1c level of 6.5% or above. Major bleeding was defined according as intracranial hemorrhage, 5 g/dL decrease in the hemoglobin concentration or a 15% absolute decrease in the hematocrit level (12) . A lifetime history of smoking 100 cigarettes was considered to be a positive smoking history (13) . Hypertension was defined as a diagnosed history of hypertension or the use of anti-hypertensive drugs. The definition of dyslipidemia included the use of lipid-lowering medications and/or a blood examination on admission showing a serum LDL-cholesterol level of 140 mg/dL or above, a serum triglyceride level of 150 mg/dL or above or a serum HDL-cholesterol level of 39 mg/dL or below. A high contrast load was defined as an administered contrast agent volume of 140 mL (14) . The Mehran risk score (MRS) includes eight clinical and procedural variables: age >75 years, anemia, diabetes, hypotension, intraaortic balloon pump (IABP) use, congestive heart failure, chronic kidney disease and the volume of contrast (15) .
Study protocol
After enrollment, the patients were randomly assigned into two groups: the remedial hydration (RH) group and the no RH group (control group). The patients were randomized 1:1 according to a computer-generated permuted block of eight patients to ensure the balanced assignment of patients to each group. The patients in the RH group received intravenous hydration with 0.9% normal saline at a rate of 1 mL/kg.hr for 12 hours after primary PCI. In patients with left ventricular dysfunction (ejection fraction 30%) or a Killip class 2 or 3 status, the rate of hydration was reduced to 0.5 mL/kg per hour. No other hydration media were used in this study, and the control group did not receive any hydration liquids. The use of beta-adrenergic blocking agents, statins, angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB), diuretics, inotropic drugs and IABP (during primary PCI or later during the hospital course) was left to the discretion of the coronary care unit cardiologists according to international guidelines (16) . All patients underwent an echocardiographic evaluation within 24 hours of hospital admission. The SCr concentration was routinely measured, and the CCr level was calculated before PCI and 24, 48 and 72 hours after PCI. A dedicated nephrologist consultant was available for the clinical care of patients with an impaired renal function during hospitalization. Relevant baseline and follow-up laboratory data and all adverse clinical events were recorded during hospitalization.
Primary PCI
Primary angioplasty was performed by a 24-hour on-call interventional team according to the standard techniques. All patients received a loading dose of 300 mg of clopidogrel, in combination with 300 mg of aspirin followed by a maintenance dose of 75 mg/day of clopidogrel with 100 mg/day of aspirin. After sheath insertion, a heparin bolus was given at a dose of 70 U/kg, followed by an additional bolus during the procedure in order to maintain an activated clotting time of more than 250 seconds, if necessary. A nonionic, low-osmolality contrast agent, iopamiron (755 mg iopamidol per milliliter, SINE, Shanghai, China), was used exclusively. The selection of the arterial access site, guide catheters, balloons and stents, contrast dose and supportive pharmacological therapies applied during the procedure was left to the discretion of the interventional cardiologist.
Statistical analysis
The statistical analysis was performed using the SPSS version 18.0 software package (SPSS Inc., Chicago, USA). Continuous data are reported as the mean ± standard deviation and were compared between the two groups using Student's t-test. Categorical data are expressed as the absolute value and percentage and were compared using the χ 2 test or Fisher's exact Test. In addition, the 95% confidence interval (CI) was calculated for treatment differences in all efficacy variables. Statistical significance was defined as a p value of <0.05.
The sample size calculation was made using an estimation of the differences in the incidence of CIN between the RH and no RH groups. Using a two-sided chi-square test and significance level of p=0.05, a total of 190 randomized patients would give the study 90% power. A sample size of over 209 patients was planned, taking into account the likelihood of the loss of patients to follow-up, protocol violations and incomplete data collection (estimated 10% total).
Results
Patient characteristics
Among a total of 256 STEMI patients, 40 were excluded (12 with cardiogenic shock, eight on chronic peritoneal or hemodialysis treatment, seven due to the inability to calculate the MRS for hemolysis of initial blood collection in the primary department, six due to a diagnosis of variant angina pectoris, three for Takotsubo cardiomyopathy, four due to interruption of the infusion of physiological saline as a result of angialgia). Ultimately, a total of 216 patients (149 men, 67 women) were randomly assigned to either the RH group (n=108) or no RH group (n=108). Table 1 shows the baseline characteristics of the patients who completed the study in both groups. The patients in the RH group were less likely to smoke. The baseline SCr and CCr values were similar in the two groups. No significant differences were observed in age, gender, body mass index (BMI), medical history, Killip class or medications between the two groups. Among the 216 patients, 154 (71.3%) received a high contrast load (contrast media volume 140 mL) (17) . Neither the volume of contrast nor ratio of a high contrast load were significantly different between the groups (p>0.05).
Incidence of CIN
According to the MRS, the average amount of 0.9% normal saline infused in the RH group was as follows: low-risk group= 0.79±1.0 mL/kg per hour; moderate-risk group= 0.77±0.9 mL/kg per hour; high-risk group= 0.74±0.9 mL/kg per hour; very-high-risk group= 0.73±0. 8 (Fig. 1) .
Changes in SCr and CCr
The changes in the SCr and CCr values from baseline to 24,48 and 72 hours are shown in Fig. 2 . There were no significant differences in the SCr values (RH; 76±14 vs. Control; 78±13 μmol/L, p>0.05) or CCr values (RH; 85±15 vs. Control; 86±16 ml/min, p>0.05) at baseline between the RH group and the control group. However, the SCr concentrations were significantly lower in the RH group than in the control group at 24 hours (RH; 78±16 vs. Control; 83±17 μmol/L, p=0.026), 48 hours (RH; 80±15 vs. Control; 85±18 μmol/L, p=0.027) and 72 hours (RH; 77±15 vs. Control; 82±16 μmol/L, p=0.018) after contrast administration. In addition, the SCr clearance rates were significantly higher in the RH group at 24 hours (RH; 82±15 vs. Control; 86±16 ml/min, p=0.043), 48 hours (RH; 80±14 vs. Control; 72±13 ml/min, p=0.030) and 72 hours (RH; 85±16 vs. Control; 80±13 ml/min, p=0.012).
In-Hospital clinical outcomes
The clinical in-hospital outcomes of the RH and no RH groups are summarized in Table 2 . A total of 13 patients died (three due to cardiogenic shock, five due to refractory heart failure, two due to multiorgan failure, one due to ischemic stroke, one due to left ventricular free wall rupture and one for other reasons). The overall in-hospital mortality rate for the entire population was 6.1% (13/216). However, the mortality rate was significantly greater in the no RH group (10/108= 9.25%) than in the RH group (3/108= 2.78%, p=0.027). The rates of in-hospital events, including serious ventricular arrhythmia, acute pulmonary edema, acute renal failure requiring temporary renal replacement therapy, the need for mechanical ventilation, cardiogenic shock requiring IABP and major bleeding requiring blood transfusion, were also lower in the RH group (p<0.05), as was the length of hospital stay (p<0.05).
Discussion
The findings of the present study can be summarized as follows. First, remedial hydration is an effective strategy for Second, the in-hospital clinical outcomes in the RH group were improved compared with those observed in the control group. Third, remedial hydration yields a benefit when the MRS is over 5, and the higher the score, the greater the benefit for the patient.
CIN
Due to hemodynamic instability, a large volume of contrast medium and the lack of effective prophylaxis, patients with STEMI undergoing primary PCI are at high risk of developing CIN (5) . Recently, various studies have demonstrated that the combination of renal insufficiency and AMI represents a high-risk condition (18) . Saline hydration remains the cornerstone of CIN prevention. This treatment results in expansion of the plasma volume with concomitant suppression of the renin-angiotensin-aldosterone system, downregulation of the tubuloglomerular feedback mecha- nism and dilution of contrast media. Therefore, hydration not only protects patients from renal vasoconstriction and tubular obstruction, but also reduces the workload and level of oxygen consumption in the renal medulla (19, 20) . Although the optimal hydration strategy remains uncertain, existing data support the use of a regimen of 0.9% sodium chloride before and after contrast administration (21). Although several studies have evaluated the efficacy of "remedial hydration" in AMI patients in preventing CIN after angioplasty, to the best of our knowledge, this is the first study to focus on the utility of remedial hydration with saline in STEMI patients treated with primary PCI. In the present study, there were no significant differences between the groups in any of the risk factors reported to be associated with the development of CIN, including gender, age, the baseline renal function, hematocrit, diabetes, amount of contrast administered, cardiogenic shock, need for intra-aortic balloon counterpulsation and intraprocedural hypotension (2, 15, 22) . There was a statistical difference in the rate of "current smoking" between the RH group and control group; however, as far as we are aware, smoking is not a risk factor for CIN. We used a single low-osmolar contrast medium throughout the entire study period in order to avoid bias and problems related to varying responses to different media.
Although the close collaboration with the local nephrologist at our hospital may have reduced the risk of CIN development, the patients in the present study exhibited a higher incidence of CIN (28%) than that reported in the study by Marenzi et al. (5) , in which CIN was defined as a 0.5-mg/ dL increase in SCr from baseline after PCI. A review of CIN definitions suggests that a move has occurred toward recognizing CIN as an increase from baseline by 25% (23) compared with an absolute increase of 0.5 mg/dL only. An additional reason for the above difference may be the use of RH in all patients in Marenzi's study.
SCr and CCr
The efficacy of the estimated glomerular filtration rate as a better parameter for estimating the renal function notwithstanding, in the present study, the well-established and simple bedside parameters of SCr and CCr were used to identify CIN. Compared with that observed in the no hydration group, remedial hydration significantly lowered the peak SCr levels at 24, 48 and 72 hours. At 72 hours after PCI, the creatinine levels in the RH group returned to the preprocedural baseline levels; however, this was not the case in the no RH group. Meanwhile, the CCr levels decreased to their lowest values at 48 hours in both groups. In the RH group, the peak CCr levels increased significantly at 24, 48 and 72 hours compared with that observed in the control group. The CCr levels recovered to the baseline values at 72 hours in the RH group, but not the control group. These findings indicate that remedial hydration is effective in protecting the kidney function and facilitating the early recovery of the kidneys.
Short-term adverse events
It has been shown that coexisting renal dysfunction, including that observed in patients who undergo successful PCI, worsens the prognosis (24) , and the in-hospital mortality of patients with an impaired renal function is markedly increased (25) . Measures to prevent the development of CIN may improve outcomes in these patients. The benefit of RH in improving short-term clinical outcomes was also observed in this study. Indeed, in the RH group, a three-fold reduction in mortality was found compared with that noted in the control group. In addition, the incidence of clinical events, including serious ventricular arrhythmia,acute renal failure requiring temporary renal replacement therapy and the need for mechanical ventilation, was dramatically decreased in the RH group compared to that observed in the control group. These data suggest that remedial hydration is a potential strategy for further reducing mortality and decreasing clinical events after primary PCI. This intervention is inexpensive and can be provided routinely after PCI without extensive advanced planning or medication. It can also be achieved using newer therapies aimed at preventing acute renal dysfunction, such as the RenalGuard System (26).
Value of the MRS in remedial hydration
The development of CIN results in a prolonged inhospital stay and represents a powerful predictor of poor early and late outcomes (27) . Careful preprocedural stratification is therefore recommended. Different scores have been developed to predict the risk of CIN among patients undergoing elective PCI (28, 29) . Nevertheless, the validity of these scores has not been previously evaluated in either context. The MRS is simple to calculate and a very useful parameter for assessing an individual patient's risk. Sgura et al. (30) reported that the MRS can be used to predict not only the incidence of CIN, but also that of short-and long-term major adverse cardiovascular and cerebrovascular events in patients treated with STEMI. In this study, the average MRS of the patients with clinical events was remarkably high (15.4±3.1 vs. 7.8±1.8, p=0.025), suggesting that the MRS is a good predictor of the risk of in-hospital events. A new aspect of the present study was to investigate which subgroups of patients, defined according to the MRS, benefit from remedial hydration and under what conditions. Interestingly, remedial hydration was found to yield a benefit when the MRS is over 5, and the higher the score, the greater benefit for the patient.
Study limitations
In interpreting these data, some limitations should be considered. First, this study was a single-center study and the sample size was small, which may have decreased the statistical power. In addition, our data were limited to the inhospital duration after the coronary procedure. Therefore, no conclusions regarding long-term follow-up outcomes can be drawn from these results. Third, the study was not blinded, which may have influenced our results. Fourth, this study does not provide any evidence of the etiology of renal function protection after remedial hydration. For example, the levels of adenosine, endothelin, malondialdehyde and oxidative stress, which may be used to evaluate other possible mechanisms, were not measured. Furthermore, a longer or shorter time of hydration may have been equally or more effective. These questions merit further study.
Conclusion
In the present study, our data suggest that remedial hydration is a potential strategy for further reducing the incidence of CIN among STEMI patients undergoing primary PCI and that this therapy is more effective in higher risk patients identified according to the MRS. In addition, remedial hydration improves the short-term prognosis of STEMI patients.
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